Drugs that contain Latanoprost; Netarsudil Dimesylate
1. Rocklatan patents expiration
ROCKLATAN's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9096569 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US8450344 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10654844 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US10174017 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US8394826 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Nov, 2030
(6 years from now) | |
| US9993470 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9931336 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US10588901 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| US9415043 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10882840 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US10532993 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11021456 | ALCON LABS INC | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
Jul, 2026
(2 years from now) | |
| US11618748 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11028081 | ALCON LABS INC | Dual mechanism inhibitors for the treatment of disease |
Jan, 2030
(5 years from now) | |
| US11185538 | ALCON LABS INC | Compositions for treating glaucoma or reducing intraocular pressure |
Mar, 2034
(9 years from now) | |
| US11197853 | ALCON LABS INC | Combination therapy |
Mar, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2022 |
| New Combination(NC) | Mar 12, 2022 |
NCE-1 date: 18 December, 2021
Market Authorisation Date: 12 March, 2019
Treatment: Reduction of elevated intraocular pressure
Dosage: SOLUTION/DROPS;OPHTHALMIC
How can I launch a generic of ROCKLATAN before it's drug patent expiration?
More Information on Dosage
ROCKLATAN family patents
